Lexaria Bioscience Corp.
156 Valleyview Road
Kelowna
British Columbia
V1X3M4
United States
Tel: 250-765-6424
Website: http://www.lexariaenergy.com
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.YEAR FOUNDED:
2004
LEADERSHIP:
CEO: Chris Bunka
FOLLOW LEXARIA BIOSCIENCE:
Tweets by Lexaria Bioscience
100 articles about Lexaria Bioscience Corp.
-
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
11/29/2022
Lexaria Bioscience Corp. announces that its patented DehydraTECH-CBD has demonstrated performance enhancements compared to one of the world's leading anti-seizure medications, Epidiolex.
-
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
11/1/2022
Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that independent review board approval has now been received for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon.
-
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
9/2/2022
Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that Catherine Turkel, PharmD, PhD has joined the board of directors of Lexaria Bioscience Corp.
-
Lexaria Receives New Patent in Mexico
8/31/2022
Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its 27th worldwide patent granted in Mexico under registration #390001.
-
Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.
-
Lexaria Discusses Valuation Metrics for Biotech Industry
8/11/2022
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following information to its stakeholders as an aid to conveniently researching and understanding various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution
8/11/2022
NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.”.
-
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
8/10/2022
Lexaria Bioscience Corp. is pleased to announce that it has received a positive full written response from the Food and Drug Administration from its pre-Investigational New Drug ("Pre-IND") meeting regarding DehydraTECH-CBD for the treatment of hypertension.
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension
8/9/2022
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.
-
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
7/14/2022
Lexaria Bioscience Corp. is pleased to announce the Company has been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan.
-
Lexaria's Human Nicotine Study Nearing Start Date
7/13/2022
Lexaria Bioscience Corp. announces the pending start of its upcoming human nicotine study NIC-H22-1.
-
Lexaria Signs Manufacturing and License Agreements with BevNology
6/21/2022
Lexaria Bioscience Corp. is pleased to announce the signing of two agreements with Atlanta-based BevNology LLC ("BevNology").
-
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
6/3/2022
Lexaria Bioscience Corp. is pleased to announce a significant exclusive* commercial licensing agreement in Japan with Premier Wellness Science Co., Ltd., ("Premier").
-
Lexaria Grants License to Valcon Medical for the European Market
6/2/2022
Lexaria Bioscience Corp. is pleased to announce the awarding of a European and United Kingdom DehydraTECH license for medical cannabis applications from Lexaria Pharmaceutical Corp. to Valcon Medical A/S ("Valcon").
-
Lexaria Announces 2022 Annual Meeting Results
6/1/2022
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting.
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space
5/26/2022
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.”
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space
5/25/2022
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.
-
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
4/21/2022
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.
-
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
4/14/2022
Lexaria Bioscience Corp. announces that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been successfully completed with positive safety and efficacy findings.
-
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
4/12/2022
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer.